• About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard
Veterinary Cannabis SocietyVeterinary Cannabis Society
  • About Us
    • Our Team
    • Our Work
    • In The News
  • Resources
    • Curated Research Library
    • Popular Articles
    • Legal Beagle Archive
    • The Education Program
    • VCS Vet Research Program
  • Directory of Practitioners
  • Get Involved
    • Become A Sponsor
    • Join Email List
  • Contact
  • SHOP NOW
    • VCS APPAREL
    • PET & PARENT JEWELRY
  • DONATE
  • Members Dashboard

The Pharmacological Case for Cannabigerol

Home The Pharmacological Case for Cannabigerol

Curated Research Library

  • Back to Curated Research Library

The Pharmacological Case for Cannabigerol

  • By: Nachnani, R., Raup-Konsavage, W.M., & Vrana, K.E.
  • Published On: 4 November, 2020
  • Publication: jpet.aspetjournals.org
  • Tags: general
  • Category: Pharmacokinetics / Pharmacodynamics

Medical cannabis and individual cannabinoids, such as D9tetrahydrocannabinol (D9-THC) and cannabidiol (CBD), are receiving growing attention in both the media and the scientific literature. The Cannabis plant, however, produces over 100 different cannabinoids, and cannabigerol (CBG) serves as the precursor molecule for the most abundant phytocannabinoids. CBG exhibits affinity and activity characteristics between D9-THC and CBD at the cannabinoid receptors but appears to be unique in its interactions with a-2 adrenoceptors and 5-hydroxytryptamine (5-HT1A). Studies indicate that CBG may have therapeutic potential in treating neurologic disorders (e.g., Huntington disease, Parkinson disease, and multiple sclerosis) and inflammatory bowel disease, as well as having antibacterial activity. There is growing interest in the commercial use of this unregulated phytocannabinoid. This review focuses on the unique pharmacology of CBG, our current knowledge of its possible therapeutic utility, and its potential toxicological hazards.

Click Here to Access Article
  • Back to Curated Research Library
Search

Our Mission is to create lasting solutions that ensure the safe use of cannabis in pets through education, advocacy, and promoting product standards.

Our Vision is an educated and empowered global veterinary medical cannabis community.

  • About Us
  • Our Work
  • Get Involved
  • Contact Us
  • Donate

Email:
Click here to email us

Florida Mailing Address
7901 4th St. North, Suite 4404
St. Petersburg, FL 33702

Veterinary Cannabis Society is a nonprofit, 501(c)(3) organization in the United States. Tax ID #85-0986090

Veterinary Cannabis Society does not endorse any specific products.

© 2025 · Veterinary Cannabis Society

  • Terms of Use
  • Privacy Policy
  • State Notices
  • Contact